Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Horizon Mutual Holdings debut $600 million senior notes offering
The investment-grade notes are due 2034
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Elevance Health $5.2 billion senior notes offering
The investment-grade notes are due 2026, 2030, 2031, 2035, 2055 and 2064
Molecular Partners $20 million follow-on offering
The ADSs are listed on the Nasdaq Global Select Market
PL Developments exchange offer and consent solicitation
The exchange offer included the issuance of new PIK toggle senior secured notes due 2029
TERUMO ¥182.5 billion secondary offering
The shares are listed on the Tokyo Stock Exchange
Roche Holdings $2.5 billion notes offering
We advised Roche on the offering comprising three tranches of notes
Inventiva private placement of up to €348 million
The offering includes ordinary shares, pre-funded warrants and warrants
Immatics $150 million follow-on offering
We advised Immatics on the offering of shares
Telemos Capital investment partnership with Helios Global Group
We are advising Telemos Capital on the transaction